Navigation Links
Frost & Sullivan: Novel Diagnostics Methods Driving the European Cancer IVD Market Towards Early Detection and Prevention
Date:2/24/2009

LONDON, Feb. 24 /PRNewswire/ -- Early detection is the key focus of cancer diagnostics. Traditional testing methods such as immunoassay testing are facing fierce competition from evolving segments such as nucleic acid amplification technology (NAT) and immunohistochemistry testing. The ability to prove the clinical utility and practical use of the test within a laboratory is one of the essential requirements to be successful in this market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com), European Cancer IVD Market, finds that the market earned revenues of $623.5 million in 2008 and estimates this to reach $1.5 billion in 2015.

"Intense research for the development of new cancer therapies is increasing the demand for tests to guide physicians in the selection of appropriate treatments," notes Frost & Sullivan Research Analyst Gayathry Ramachandran. "Repeated test requests, especially for prostrate specific antigen (PSA) will boost market revenues."

The increased prevalence of cancer has resulted in the development of novel technologies that support the effective diagnosis of cancer. Rising awareness, paralleled by the mounting use of cancer screening tests will promote the growth of the European cancer IVD market over the long term.

The importance of molecular tests has been elucidated by the success of the human genome project. This has allowed the rapid proliferation of specific nucleic acid tests for the detection of tumour markers and this trend holds strong potential for the growth of the market.

"The human genome project has encouraged the cancer genome project, where high throughput techniques are developed to d
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... ,, NEW YORK, Dec. 14 /PRNewswire-USNewswire/ -- ... (MTF) -- the largest survey on teen drug abuse ... underscores that teens, intentional abuse of prescription (Rx) and ... concern, with an alarming number of young people abusing ... Teen Abuse of Medication Continues to Be ...
(Date:12/14/2009)... SANTA ANA, Calif., Dec. 14 Grubb & Ellis ... directors has authorized a daily distribution to stockholders of record ... the period commencing on Jan. 1, 2010 and ending on ... on 365 days in the calendar year and will be ... a purchase price of $10.00 per share. These distributions ...
(Date:12/14/2009)... On December 9, 2009, the United States ... position that private insurance companies are "plans" and therefore ... other federal courts have held that contracts issued by ... Title 18 Section 1347, US vs. Frost ... been held to be a "plan," because, as the ...
(Date:12/14/2009)... hadn,t spread, study finds , , MONDAY, Dec. 14 (HealthDay ... death in male colon cancer survivors, researchers report. , ... men who,d been treated for stage I, stage II ... (nonmetastatic cancer). Every two years, the men were sent ... disease diagnoses, as well as their physical activity. A ...
(Date:12/14/2009)... shouldn,t worry most users, researcher says , , MONDAY, Dec. ... may have a small but statistically significant increased risk ... the medications, a new study finds. , "But statistical ... Jordan W. Smoller, an associate professor of psychiatry at ... in the Dec. 14 issue of Archives of ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3
... New Study in the Journal of Cosmetic Dermatology Finds Over-the-Counter ... for Helping to Clear Up Mild to Moderate EczemaEDISON, N.J., ... looking for a cost-effective way to control and heal this ... to consider. A new study in the March 2009 issue ...
... Surge in anxiety-linked hormone worsens blood sugar level, researchers suggest ... a key role in the development of type 2 diabetes ... has been given to the role of obesity in the ... important in this at-risk population," study co-author Anastasia Georgiades, of ...
... Inc. (NYSE: MED ) announced today that it ... for the period ended December 31, 2008 on Thursday, March ... Company will hold a conference call and web cast to ... a.m. ET.Interested parties can access the call by dialing (877) ...
... Minn., March 5 People across the country are now ... from Upsher-Smith Laboratories, Inc. AmLactin(R) Foot Cream Therapy provides ... dry and chapped feet because of its high concentration of ... Dry, chapped feet are the result of various factors ...
... Susan Dell Foundation awards grant totaling more than $3 ... -AUSTIN, Texas, March 5 The Michael & Susan ... The University of Texas School of Public ... expansion of the Coordinated Approach To Child Health (CATCH) ...
... Approvals for Intravenous Formulation of Temozolomide As Well As ... 5 Schering-Plough Corporation (NYSE: SGP ) ... FDA both approved the intravenous (IV) formulation of temozolomide ... of the drug. Temozolomide is marketed as TEMODAL(R) ...
Other Medicine News:Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 2Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 3Health News:Stress May Raise Diabetes Risk for Obese Black Women 2Health News:Medifast, Inc. to Announce Fourth Quarter and Fiscal Year 2008 Financial Results on Thursday, March 12, 2009 2Health News:New AmLactin(R) Foot Cream Immerses Feet in Moisture 2Health News:UT School of Public Health Program to Prevent Childhood Obesity Expands to Central Texas Middle Schools 2Health News:UT School of Public Health Program to Prevent Childhood Obesity Expands to Central Texas Middle Schools 3Health News:UT School of Public Health Program to Prevent Childhood Obesity Expands to Central Texas Middle Schools 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7
(Date:12/14/2009)... -- Travelers of Interstate 70 west of Indianapolis will ... more colorful when 10 multicolored art forms are installed ... going home , will eventually include 34 total pieces ... at Herron School of Art and Design, through the ... ,, Eli Lilly and Company (NYSE: LLY ...
(Date:12/14/2009)... Pa., Dec. 14 CPG International, ... engineered building products, introduces VYCOM, a rebranded ... the previous VYCOM Corporation and Scranton Products ... wholly recognized business unit within CPG International, ... Products Commercial. The VYCOM business unit has ...
(Date:12/14/2009)... Pharmaceutical Inc. (OTC Bulletin Board: OHRP) announced today ... in Irvine, CA, with offices also in New ... relations and corporate communications. Ohr Pharmaceutical is ... advanced drugs for underserved therapeutic needs. The Company ... markets: OHR/AVR118 for the treatment of Cachexia and ...
Breaking Medicine Technology:Public Art to Complete Transformation of Key Gateway into Indianapolis 2Public Art to Complete Transformation of Key Gateway into Indianapolis 3Public Art to Complete Transformation of Key Gateway into Indianapolis 4Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 2Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 3Milwaukee Employers See Cost Savings with High Performance Provider Network 61921 1Milwaukee Employers See Cost Savings with High Performance Provider Network 61921 2Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 1Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 2Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 3Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 4Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 5Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 1Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 2
... and REBETOL(R) will be the only available hepatitis C therapy, approved ... ... approval, KENILWORTH, ... that the Committee for Medicinal,Products for Human Use (CHMP) of the ...
... Sept. 24 Knopp Neurosciences Inc. ("Knopp"),today ... clinical trial of KNS-760704, a,small molecule therapy ... sclerosis (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ... ascending,dose study in healthy volunteers is being ...
Other Medicine Technology:European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 2European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 3European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 4European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 5European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 6European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 7European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 8Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 2Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: